• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MDS Pharma Revenues Continue to Fall

MDS Pharma Revenues Continue to Fall

December 18, 2008
CenterWatch Staff

Canadian life science company MDS, the parent company of King of Prussia, Pa.-based MDS Pharma Services, released fourth quarter results reflecting another disappointing quarter for its embattled contract research organization (CRO) division. Net revenues for MDS Pharma were $112 million, down 9% from the same quarter last year.

These financials come one month after a major shareholder pressured company leaders to sell off several business units including MDS Pharma in order to increase shareholder value. Earlier this month, MDS lowered its financial guidance for the third time this year.

“In Q4, we saw growth in early stage phase I and bioanalytical. This growth, however, was offset by delays in phase II through phase IV as customers continue to reprioritize their pipelines during these uncertain times,” said MDS president and CEO Stephen DeFalco in Wednesday’s investor conference call.

MDS also expects a non-cash write-down of $270 million to $370 million for its CRO division as a result of “the decline in overall stock market valuation of the contract-research sector, the uncertain economic outlook and the delay in profit recovery at MDS Pharma Services,” according to a company release. The final amount of this write-down will be released in January with the company’s audited financial statements.

The CRO did see an EBITDA gain in the fourth quarter from $1 million in the fourth quarter of 2007 to $8 million in the fourth quarter of 2008, but this gain was largely the result of major restructuring efforts started this summer, including the laying off of more than 150 MDS Pharma employees.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing